Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online November 2, 2022.
Article Versions
- Latest version (October 15, 2022 - 04:05).
- Latest version (November 1, 2022 - 09:40).
- You are currently viewing a Latest version of this article (November 2, 2022 - 10:25).
- latest version (February 1, 2023 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2022 The Journal of Rheumatology
Author Information
- Laura C. Coates,
- Irene van der Horst-Bruinsma,
- Ennio Lubrano,
- Steph Beaver,
- Emma Drane,
- Baran Ufuktepe and
- Alexis R.Ogdie
- LCC: MBChB, MRCP, PhD. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, Oxfordshire, UK
- IEvdHB:MD, PhD. Department of Rheumatology, ZH0D53, Amsterdam UMC/VU University Medical Centre, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
- EL: MD, MSc, PhD, Dipartimento di Medicina e Scienze, Della Salute "Vincenzo Tiberio", Università degli Studi del Molise, Via Giovanni Paolo II, C/da Tappino, 86100, Campobasso, Italy
- SB: MSc, Costello Medical Consulting Ltd, Cambridge, Cambridgeshire, UK
- ED: PhD, Costello Medical Consulting Ltd, Cambridge, Cambridgeshire, UK
- BU: MD, PhD, UCB Pharma A.S (Turkey), Istanbul, Turkey
- ARO: MD, MSCE, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
-
This study was sponsored by UCB Pharma. Support for third-party writing assistance for this article, provided by Costello Medical, was funded by UCB Pharma in accordance with Good Publication Practice (GPP3) guidelines. (http://www.ismpp.org/gpp3).
Conflict of Interest: LCC: Grant/research support from AbbVie, Amgen, Celgene, Gilead, Janssen, Lilly, Novartis, Pfizer, UCB Pharma; Consulting fees from: AbbVie, Amgen, Biogen, Boehringer Ingelheim, Celgene, Domain, Gilead, Janssen, Lilly; Speaker's bureau for: AbbVie, Amgen, Biogen, Celgene, Gilead, GSK, Janssen, Lilly, Medac, Novartis, Pfizer and UCB Pharma. IEvdHB: Grant/research support from AbbVie, MSD, Pfizer; Consultant for AbbVie, MSD, Novartis, UCB Pharma; Speaker's bureau: AbbVie, BMS, MSD and Pfizer. EL: Consultant for AbbVie, Celgene, Novartis, Pfizer and UCB Pharma. SB, ED: Employees of Costello Medical. BU: Employee of UCB Pharma. ARO: Grant/research support to researcher's institution from Pfizer Novartis to Penn, Amgen to Forward/NDB; Consultant for: AbbVie, Amgen, BMS, Celgene, Corrona, Eli Lilly, Janssen, Novartis and Pfizer.
Correspondence to: Laura C Coates, University of Oxford, Oxford, UK. Email: laura.coates@ndorms.ox.ac.uk